BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yi ES, Son MH, Hyun JK, Cho HW, Ju HY, Lee JW, Yoo KH, Sung KW, Koo HH. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer 2020;67:e28066. [PMID: 31736249 DOI: 10.1002/pbc.28066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Ehlert K, Hansjuergens I, Zinke A, Otto S, Siebert N, Henze G, Lode H. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. J Immunother Cancer 2020;8:e000540. [PMID: 32414861 DOI: 10.1136/jitc-2020-000540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
2 Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Ikawa Y, Fujiki T, Akatani N, Yamase T, Watanabe S, Hiromasa T, Kunita Y, Mori H, Saito S, Nishimura R, Wada T, Kinuya S. High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience. Ann Nucl Med 2020;34:840-6. [PMID: 32862362 DOI: 10.1007/s12149-020-01514-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kuroda R, Wakabayashi H, Araki R, Inaki A, Nishimura R, Ikawa Y, Yoshimura K, Murayama T, Imai Y, Funasaka T, Wada T, Kinuya S. Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 34837510 DOI: 10.1007/s00259-021-05630-7] [Reference Citation Analysis]